AC x 4 followed by CMF x 3 with or without a chemotherapy-free interval, +/- tamoxifen vs. toremifene for post/perimenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone

Study Chairs
Dr. Olivia Pagani - Mendrisio, Switzerland
Dr. Edda Simoncini - Brescia, Italy

Shari Gelber

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
May 1993

Date of Closure
August 1, 1999

Targeted Accrual
884 patients

Final Accrual
969 patients

Date of Discontinued Follow-up

December 31, 2010

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Phone: +41 31 511 94 00

Member Login